6-isopropoxy-hex-1-yne | 1036387-38-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-isopropoxy-hex-1-yne
• 英文别名: 6-Propan-2-yloxyhex-1-yne
• CAS: 1036387-38-8
• 化学式: C₉H₁₆O
• 分子量: 140.225
• InChiKey: BYBMFAJJDKYFDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] POLYOXAZOLINE ANTIBODY DRUG CONJUGATES<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT DE POLYOXAZOLINE
  申请人：SERINA THERAPEUTICS INC

  公开号：WO2016019340A1

  公开（公告）日：2016-02-04

  In the present disclosure, polymer conjugates, including polymer-antibody-drug conjugates (polymer ADCs) are described, as well as the use of such conjugates to treat human disease. The polymer conjugates can contain a large number of polymer-bound agents, thus effectively increasing the drug antibody ration (DAR) of the antibody significantly beyond the currently available technology. This may be of particular importance when antibodies to low density antigens are used as target antibodies. The described polymer-ADCs have improved pharmacokinetics and solubility relative to traditional ADCs. The linker between agent and the polymer can be tailored to provide release of toxin at the desired site and under the desired conditions within the tumor. An additional feature of the polymer-ADCs of the current disclosure is that a purification moiety can be attached to the polymer backbone to provide ease of purification of the polymer-ADCs.

  本公开描述了聚合物偶联物，包括聚合物-抗体-药物偶联物（聚合物ADCs），以及使用这些偶联物治疗人类疾病。该聚合物偶联物可以含有大量的聚合物结合剂，从而有效提高抗体的药物抗体比率（DAR），显著超过目前现有技术。当使用针对低密度抗原的抗体作为靶点抗体时，这一点可能尤为重要。与传统的ADC相比，所述聚合物ADC具有改善的药代动力学和溶解性。毒素与聚合物之间的连接器可以根据需要在肿瘤内特定部位和特定条件下释放毒素进行定制。当前公开的聚合物ADC的另一个特点是，可以在聚合物主链上附着一个纯化部分，以提供聚合物ADC的纯化便利。
• Sphingosine-1-phosphate receptor agonist and antagonist compounds
  申请人：Wallace Grier A.

  公开号：US20090029947A1

  公开（公告）日：2009-01-29

  The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.

  本发明涉及一种新型、有效和选择性的药剂，它们是S1P受体家族中一个或多个单个受体的激动剂或拮抗剂。本发明的化合物可用作治疗与S1P受体家族中单个受体的激动或拮抗有关的医学状况的治疗剂。
• US8217027B2
  申请人：——

  公开号：US8217027B2

  公开（公告）日：2012-07-10
• [EN] SPHINGOSINE-1 -PHOSPHATE RECEPTOR AGONIST AND ANTAGONIST COMPOUNDS<br/>[FR] COMPOSÉS D'AGONISTES ET D'ANTAGONISTES DES RÉCEPTEURS DE SPHINGOSINE-1-PHOSPHATE
  申请人：ABBOTT LAB

  公开号：WO2008079382A1

  公开（公告）日：2008-07-03

  [EN] The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.
  [FR] L'invention concerne de nouveaux et puissants agents sélectifs étant des agonistes ou des antagonistes d'un ou plusieurs récepteurs individuels de la famille des récepteurs de S1P. Les composés selon l'invention servent d'agents thérapeutiques pour traiter des troubles médicaux associés à l'agonisme ou à l'antagonisme des récepteurs individuels de la famille des récepteurs de S1P.